Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib’s for MF and Potential in ET Reviewed

Blood; ePub 2017 May 12; Bose, Verstovsek

Since its approval in 2011, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis, and its use in patients with hydroxyurea resistant/intolerant polycythemia vera is steadily increasing, according to a recent review.

The authors note that a number of other JAK2 inhibitors have entered clinical testing, but, given the proven safety and efficacy of ruxolitinib, it is likely that ruxolitinib-based combinations will be a major way forward in drug development for myelofibrosis. They also point out that ruxolitinib is in late phase clinical trials in essential thrombocythemia.

Citation:

Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: What is next? [Published online ahead of print May 12, 2017]. Blood. doi:10.1182/blood-2017-04-742288.